Chemistry:Pipendoxifene

From HandWiki
Short description: Chemical compound
Pipendoxifene
Pipendoxifene skeletal.svg
Clinical data
Other namesERA-923
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC29H32N2O3
Molar mass456.586 g·mol−1
3D model (JSmol)

Pipendoxifene (INN) (developmental code name ERA-923) is a nonsteroidal selective estrogen receptor modulator (SERM) that was under development by Ligand Pharmaceuticals and Wyeth-Ayerst Laboratories (now Wyeth) for the treatment of breast cancer but was not marketed.[1][2][3] It is a member of the 2-phenylindole group of SERMs and is structurally related to zindoxifene and the marketed bazedoxifene.[2][3] The drug reached phase II clinical trials before its development was discontinued.[1][2] It was synthesized at the same time as bazedoxifene and was intended as a backup drug for bazedoxifene, only to be developed further if bazedoxifene had failed in clinical trials.[1][2] No further development was reported after 2002 and it was formally announced that development had been terminated in November 2005.[1][4]

Unlike the SERM raloxifene, pipendoxifene is devoid of uterotrophic activity in immature/ovariectomized rodents.[3][5]

References

External links